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Tuberous sclerosis complex (TSC) is a genetic disorder with pleiotropic manifestations caused by heterozy-
gous mutations in either TSC1 or TSC2. One of the less investigated complications of TSC is the formation of
aneurysms of the descending aorta, which are characterized on pathologic examination by smooth muscle
cell (SMC) proliferation in the aortic media. SMCs were explanted from Tsc21/2 mice to investigate the patho-
genesis of aortic aneurysms caused by TSC2mutations. Tsc21/2 SMCs demonstrated increased phosphoryl-
ation of mammalian target of rapamycin (mTOR), S6 and p70S6K and increased proliferation rates compared
with wild-type (WT) SMCs. Tsc21/2 SMCs also had reduced expression of SMC contractile proteins compared
with WT SMCs. An inhibitor of mTOR signaling, rapamycin, decreased SMC proliferation and increased con-
tractile protein expression in the Tsc21/2 SMCs to levels similar to WT SMCs. Exposure to a-elastin frag-
ments also decreased proliferation of Tsc21/2 SMCs and increased levels of p27kip1, but failed to increase
expression of contractile proteins. In response to artery injury using a carotid artery ligation model,
Tsc21/2 mice significantly increased neointima formation compared with the control mice, and the neointima
formation was inhibited by treatment with rapamycin. These results demonstrate that Tsc2 haploinsufficiency
in SMCs increases proliferation and decreases contractile protein expression and suggest that the increased
proliferative potential of the mutant cells may be suppressed in vivo by interaction with elastin. These
findings provide insights into the molecular pathogenesis of aortic disease in TSC patients and identify a
potential therapeutic target for treatment of this complication of the disease.
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder with pleiotropic manifestations due to mutations in
either TSC1 (hamartin) or TSC2 (tuberin) (1–3). The disorder
affects the brain (cortical and subcortical tubers, subependy-
mal nodules and giant cell astrocytomas), kidneys (angiomyo-
lipomas, cysts, carcinoma), skin (hypomelanotic macules,
shagreen patches, facial angiofibromas, periungual fibromas),
eyes (retinal hamartomas), heart (rhabdomyomas) and other
organs. TSC1 and TSC2 are ubiquitously expressed and
form heterodimers that inhibit the activation of mammalian
target of rapamycin (mTOR) signaling (4–6). The TSC1/
TSC2 complex negatively regulates mTOR through
GTPase-activating protein (GAP) activity directed at the
small GTPase Rheb (Ras homolog enriched in brain), which
binds and activates mTOR. When associated with the proteins
raptor and mLST8, mTOR exists in a rapamycin-sensitive
complex, termed mTORC1. Loss of either TSC1 or TSC2
abolishes the Rheb-GTPase activity, resulting in constitutively
activated mTORC1. The activated mTORC1 kinase then
enhances protein translation by phosphorylation of S6K1 and
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eukaryotic translation-initiation factor 4E-binding protein 1
(4E-BP1) (7–9). S6K1 is a kinase that activates ribosomal
subunit protein S6, leading to ribosome recruitment and
protein translation. 4E-BP1 inhibits the activity of eukaryotic
translation-initiation factor 4E (eIF4E), and when phosphory-
lated by mTORC1, releases eIF4E from its control (10).
Therefore, mTORC1 activation promotes cell growth, cell
cycle progression and proliferation, in part by increasing the
anabolic process of protein synthesis through the activation
of S6K and the inhibition of 4E-BP1 (11,12).
An unusual and less recognized complication of TSC is vas-
cular abnormalities, which include very premature onset of
aortic aneurysms in infants, children and young adults. Aortic
aneurysms are extremely rare in infants, and the youngest
reported TSC case is an infant who died of aortic aneurysm
rupture at the age of 4.5 months (13). TSC patients primarily
have abdominal aortic aneurysms and the majority of these
aneurysms occur in children below the age of 5 years. The
pathogenesis of aortic aneurysms in these TSC patients
remains largely unknown despite the fact that these aneurysms
can lead to premature death in TSC (13–17). Surprisingly, none
of the case reports in the literature indicates whether the aortic
aneurysms were associated with TSC1 or TSC2 mutations.
Vascular smooth muscle cells (SMCs) are not terminally dif-
ferentiated and maintain a phenotypic plasticity that allows for
transition from quiescent, differentiated cells expressing a
repertoire of proteins required for contractile function
(a-actin, calponin and b-myosin heavy chain) to proliferating,
migrating cells with loss of contractile protein expression and
increased synthesis of extracellular matrix proteins. SMCs are
differentiated cells in a mature, functional artery but
de-differentiate with vascular injury and environmental cues.
In SMCs, mTORC1 signaling is already known to influence
SMC differentiation; inhibition of mTORC1 signaling with
the macrolide antibiotic rapamycin promotes SMC differen-
tiation through the activation of the Akt pathway and the induc-
tion of contractile protein expression (18,19).
We confirmed a TSC2 mutation in a 3-year-old male with a
large thoracoabdominal aneurysm. On the basis of this knowl-
edge, we investigated the role of TSC2 deficiency on aortic
SMC differentiation and proliferation using a heterozygous
Tsc2-deficient mouse model. We found that the activation of
the mTORC1 pathway with Tsc2 deficiency leads to SMC pro-
liferation and de-differentiation in vitro and in vivo, which can
be reversed with rapamycin treatment. Interestingly, exposure
to a-elastin peptides also reduced Tsc2þ/2 SMC proliferation
but did not increase the expression of contractile proteins in
the mutant SMCs in vitro.
RESULTS
Descending aortic aneurysm associated with subintimal
SMC proliferation in a child with a TSC2 mutation
An African-American boy was diagnosed with TSC at 5 months
of age when he presented with generalized tonic–clonic sei-
zures and multiple hypopigmented macules. Computerized
tomography of the brain at that time showed multiple subepen-
dymal nodules, and tubers in the left parietal and frontal lobes.
Genetic testing identified a 32 bp deletion from the nucletide
position of 5340–5371 in TSC2, codon position 1780–1791,
which causes a frame shift mutation and truncation of the
protein. Analysis of the parents’ DNA determined that the
mutation was de novo. At the age of 3 years, a magnetic reson-
ance angiogram (MRA) revealed a complex thoracoabdominal
aneurysm with three discrete fusiform dilations, with the
widest transverse diameter measuring 7 cm and spanning a
length of 12 cm (Fig. 1A). The patient underwent surgical
repair of the aneurysm, and the pathology of the aorta was exam-
ined. The control aorta demonstrated typical organization of the
aortic media composed of layers of elastic fibers, with SMCs
between these layers. The patient’s aorta showed areas of rela-
tively normal aortic media, along with regions of excessive
extracellular matrix deposition and nodules of SMCs, confirmed
by SMC a-actin staining (Fig. 1C, arrows). Movat pentachrome
staining of the aorta confirmed that the SMC proliferation was
associated with collagen deposition and occurred in the subinti-
mal layer of the aortic media (Fig. 1C, blue arrowheads indicate
the internal elastic lamina—IEL).
Ten months after the initial repair, the patient was clinically
asymptomatic on a b-adrenergic blocker but a CT angiography
showed new aortic enlargement in the thoracic part of the
aorta, the largest transverse diameter measuring 6.5 cm
(Fig. 1B). He underwent a second surgical repair. The his-
tology was identical with the previous specimen, except for
increased loss of SMCs in the muscular media. He tolerated
surgical repair, and 12 months after the second repair, no
recurrence of the aneurysm was evident.
Increased proliferation and decreased contractile protein
expression in Tsc21/2 SMCs
The unique presentation of an aneurysm in a child with a TSC2
mutation and the associated aortic subintimal SMCs prolifer-
ation led us to study the effect of Tsc2 mutations on vascular
SMCs using a mouse model with the deletion of one allele of
the Tsc2 gene (20,21). On the basis of aortic disease presenting
in the descending aorta in TSC patients, we hypothesized that
loss of TSC2 would have a differential effect on SMCs of
mesodermal origin (descending aorta) versus SMCs that
were neural crest-derived (ascending aorta) (22). Therefore,
we explanted SMCs of wild-type (WT) and Tsc2þ/2 mice
from the ascending and descending aorta separately, seeded
the cells at the same density with serum deprivation and
assessed proliferation by bromodeoxyuridine (BrdU) incorpor-
ation in SMCs. In WT SMCs, proliferation rates did not differ
between ascending and descending aortic SMCs (Fig. 2A).
The Tsc2þ/2 SMCs from both the ascending and descending
aorta proliferated significantly more rapidly than the WT
SMCs, with mutant SMCs from descending aorta proliferated
significantly faster than cells explanted from the ascending
aorta. Since the descending aorta is primarily involved in
TSC patients, further experiments were focused primarily on
the descending aortic Tsc2þ/2 SMCs. To examine the cell
cycle progression of descending aortic SMCs, cell cycle distri-
bution was analyzed by flow cytometric cell-sorting technique
(Fig. 2B). Cell numbers at S and G2/M phases were increased
in SMCs explanted from the Tsc2þ/2 SMCs compared with
the WT SMCs, indicating that more Tsc2þ/2 cells have
entered the cell cycle for proliferation. TSC1/TSC2 acts to
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suppress mTORC1 activity, therefore suppressing downstream
phosphorylation of S6K and 4E-BP1 (23,24). Immunoblot
analysis confirmed increased phosphorylation of Thr389 of
S6K in the Tsc2þ/2 descending aortic SMCs compared with
WT cells (Fig. 2C). Activation of S6K was also reflected in
the increased phosphorylation of its substrate, S6, at both
Ser240 and Ser244.
We also sought to determine whether Tsc2þ/2 SMCs were
de-differentiated through the assessment of expression of
several contractile proteins, including a-actin (Acta2), calpo-
nin (Cnn1), b-myosin (Myh11) and muscular g-actin
(Actg2), by quantitative real-time PCR (qPCR) in Tsc2þ/2
SMCs (Fig. 2D). By qPCR, expression of all these contractile
proteins were decreased in the mutant SMCs, with the differ-
ences more marked in SMCs explanted from the descending
aorta compared with ascending aorta. In contrast, expression
of the cytoskeleton proteins b-actin (Actb) and g-actin
(Actg1) were similar between the WT and mutant SMCs
Figure 1. MRA and pathological examination of the aorta of a patient with TSC2 mutation. (A) A coronal maximum intensity pixel reconstruction from
contrast-enhanced MRA demonstrates a multilobulated aneurysm (arrows) involving the distal thoracic and abdominal aorta, with extension below the renal
arteries. The distal thoracic aorta harbored the most proximal aneurysm dilation, measuring 2.8 cm in length and 2.4 cm at its greatest diameter. The second
fusiform dilation was located in the proximal abdominal aorta, which was 5.3 cm in length, and from which the celiac artery arose. The third fusiform dilation
involved the origins of the superior mesenteric artery and both renal arteries. The distal abdominal aorta was normal in caliber, with no involvement of the
common iliac arteries. (B) A chest CT with contrast shows two aneurysms in the general region of the proximal and distal graft anastomosis. The first aneurysm
is located in the descending thoracic aorta extending anteriorly from the aorta/graft at the level of T8 to L1 and measuring about 6.5 cm in transverse and 3.5 cm
in AP dimension. There is a thrombotic layer around the aneurysm that measures about 1.2 cm in thickness. The second aneurysm originates at the level of L1–
L2 and extends anteriorly from the abdominal aorta, measuring 3.2 cm in AP dimension  3 cm transversely, and involves the origin of the right renal artery. (C)
H&E, SMC a-actin and Movat pentachrome staining of aortas from control and TSC patient. H&E staining demonstrates SMC disarray and hyperplasia in the
subintimal layer of the media in patient with TSC2 mutation. a-Actin staining confirms the nodules of cells in the subintimal layer are SMCs in patient’s aorta.
SMCs in the affected areas of the aorta and from control aorta were quantified by images collection from five fields of vision at 400 magnification. Counting of
the SMCs confirmed a significant increase of SMCs in patient’s affected aorta (P, 0.005). Movat staining shows medial disruption in the aorta of the TSC
patient that is characterized by nodules of SMCs (red), accumulation of collagen (yellow) and loss and fragmentation of elastic fibers (black). Arrowheads indi-
cate the location of the IEL (stained black), confirming that the pathology occurs primarily in the subintimal layer. Magnification is indicated on each set of
panels.
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(Fig. 2D). Immunoblot analysis of Tsc2þ/2 descending SMCs
compared with WT confirmed decreased protein levels of
SMC a-actin and calponin (Fig. 2E). Interestingly, expression
of S100A4 was greatly increased in the Tsc2þ/2 SMCs, with a
more dramatic increase noted in the descending mutant SMCs.
S100A4 has been shown to be increased in de-differentiated
SMCs with enhanced proliferation when compared with dif-
ferentiated, nonproliferating SMCs (25).
Inhibition of mTORC1 signaling decreases proliferation
and increases contractile protein expression in Tsc21/2
SMCs
In order to determine whether the increased proliferation
and de-differentiation of Tsc2þ/2 SMCs were due to
augmented mTORC1 activity, rapamycin was used to inhibit
mTORC1 activity. Rapamycin inhibits mTORC1 through the
association with its intracellular receptor, FKBP12, and the
FKBP12-rapamycin complex binds directly to the
FKBP12-rapamycin-binding (FRB) domain of mTOR (26).
After 24 h of rapamycin treatment, phosphorylation of S6K
and S6 was decreased in the Tsc2þ/2 and WT cells and
remained suppressed for 72 h of rapamycin treatment
(Fig. 3A). Rapamycin treatment decreased the proliferation
of both the WT and Tsc2þ/2 aortic SMCs, suppressing the
proliferation of mutant SMCs to the WT level after 72 h of
treatment (Fig. 3B). Furthermore, the number of WT and
mutant cells in S and G2/M phases was significantly decreased
after treatment with rapamycin (Fig. 3C). These results
indicated that rapamycin inhibited SMC proliferation by
causing cell cycle arrest at G0/G1 phase, therefore blocking
the G1/S transition during cell division in Tsc2þ/2 SMCs.
We also determined whether the decreased proliferation of
Tsc2þ/2 SMCs with rapamycin treatment was associated
Figure 2. Tsc2þ/2 SMCs demonstrate increased proliferation and decreased expression of contractile proteins. (A) BrdU assay demonstrates that cell prolifer-
ation in Tsc2þ/2 mouse SMCs was increased compared with WT SMCs. Proliferation of Tsc2þ/2 SMCs explanted from descending aorta is significantly higher
than SMCs explanted from the ascending aorta. (B) Effects of Tsc2þ/2 on cell cycle distribution. After staining with PI, cell cycle distribution was analyzed
using a flow cytometer. The data indicated that the number of Tsc2þ/2 SMCs were significantly decreased in G0/G1 phase and significantly increased in S and
G2/M phases compared with WT SMCs. Data are reported as means+SD of three independent experiments. (C) Increase of the phosphorylation of proteins
involved in mTOR signaling pathway in cell lysates from the Tsc2þ/2 SMCs compared with WT SMCs. (D) qPCR analysis of mRNA isolated from SMCs from
WT and Tsc2þ/2 aorta. The SMCs explanted from ascending and descending aorta demonstrate that Tsc2þ/2 SMCs have significantly reduced expression of
SMC contractile genes, including Acta2, Cnn1 and Actg2. In contrast, SMCs from both Tsc2þ/2 and WT mice express similar amounts of cytoskeletal genes,
including Actg1 and Actb. Tsc2þ/2 SMCs significantly increase expression of SMC de-differentiation marker, S100A4, particularly SMCs explanted from the
descending aorta. Gene expression levels are standardized to Gapdh. P , 0.05, P , 0.01, P , 0.001. (E) Immunoblot analysis of SMC lysates confirms
reduced levels of SMC contractile protein in SMCs explanted from Tsc2þ/2 aorta compared with those from WT mice. Protein levels are normalized to Gapdh.
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Figure 3. Phenotypic abnormalities in Tsc2þ/2 SMCs are reversed by blocking mTOR signaling with rapamycin treatment. (A) Rapamycin treatment inhibited the
phosphorylation of pS6 and p70 S6K in both mutant and WT cells. (B) BrdU assay demonstrates that rapamycin significantly inhibits SMC proliferation, especially the
SMCs explanted fromTsc2þ/2 aorta. (C) SMC cell counts by FACS analysis demonstrate that the number ofTsc2þ/2 SMCs in G0/G1 phase is decreased and cells in S
and G2/M phases increased compared with WT SMCs. Quantitative assessment of the percentage of SMCs at G0/G1, S and G2/M phases after treatment with rapa-
mycin indicates that rapamycin induces cell cycle arrest at G0/G1 phase. Data are reported as means+SD of three independent experiments. (D) qPCR analysis of
mRNA isolated from SMCs from WT and Tsc2þ/2 aorta indicates that expression of SMC contractile genes (Acta2,Cnn1,Myh11,Actg2) significantly increases after
treatment with rapamycin, and expression of S100A4 significantly decreases. RNA levels were normalized to Gapdh. (E) Protein levels of SMC contractile proteins,
Cnn1 and Acta2, in SMCs explanted from control andTsc2þ/2 after treated with rapamycin. Protein levels were normalized to Gapdh. (F) Immunofluorescence analy-
sis of a-actin and stress fibers in cultured SMCs from control and Tsc2þ/2 aorta. SMC nuclei were counterstained with DAPI (blue). Magnification 600.
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with increased expression and protein levels of contractile pro-
teins. qPCR of Acta2, Myh11, Cnn1 and Actg2 confirmed that
the gene expression of these contractile proteins progressively
increased after the treatment with rapamycin, rising to levels
similar to controls (Fig. 3D). A similar increase in these con-
tractile proteins was found by immunoblot analysis. Although
Acta2 mRNA expression rose for 48 h, then declined at 72 h,
the protein levels continued to accumulate (Fig. 3D and E).
Interestingly, expression of cytoskeletal genes, Actb and
Actg1, increased in response to rapamycin in both the WT
and mutant SMCs. After treatment with rapamycin within
24 h, S100A4 decreased significantly to levels equal with
WT levels after 72 h (Fig. 3D).
Immunofluorescence using an antibody directed against
a-actin was used to confirm that rapamycin treatment of
Tsc2þ/2 SMCs promoted assembly of contractile filaments.
a-Actin is incorporated into actin filaments of the contractile
unit in vascular SMCs, whereas b-actin is found in the actin
filaments of the cytoskeleton (27). Antibodies specific for
a-actin were used (green fluorescence) and all actin filaments,
including b-actin-containing cytoskeleton filaments (stress
fibers), were visualized with phalloidin (red fluorescence).
WT SMCs showed organized stress fibers containing a-actin
spanning the cell body, whereas Tsc2þ/2 SMCs showed
normal actin stress fiber formation but diminished staining
for a-actin (Fig. 3F and Supplementary Material, Fig. S1).
After treatment with rapamycin, Tsc2þ/2 SMCs showed well-
organized stress fibers spanning the cell body containing
a-actin similar to the WT SMCs. Therefore, rapamycin
reversed the de-differentiated phenotype of the Tsc2þ/2
SMCs, specifically decreasing proliferation and increasing
expression and assembly of contractile proteins.
Tsc21/2 mice have increased neointima formation and
vessel lumen occlusion in response to arterial injury
Initial assessment of the ascending, descending and abdominal
aorta showed normal aortic architecture with intact layers of
elastin lamellae and SMCs located between the lamellae in
both the WT and Tsc2þ/2 mice (data not shown). To
examine SMC proliferation in vivo, we used an established
vascular injury protocol (28); the left common carotid artery
was ligated near its bifurcation in WT and Tsc2þ/2 mice
and the arteries were harvested at 21 days. Histological exam-
ination of the uninjured carotid arteries from WT and Tsc2þ/2
mice demonstrated the absence of a neointima formation and
no structural differences in vessel architecture (Fig. 4A).
Detailed morphometric analysis revealed that the injured
arteries isolated from Tsc2þ/2 mice had a 4-fold increase in
neointimal area compared with WT controls (Fig. 4B). The
intimal/medial (I/M) ratios of the injured arteries in Tsc2þ/2
mice were 3-fold higher than those of WT controls. Further-
more, Tsc2þ/2 mice had a 5-fold increase in percent lumen
stenosis in response to injury compared with that of WT
mice, all data supporting increased proliferation of the
mutant SMCs in vivo.
We also tested whether administration of rapamycin could
inhibit neointima formation in Tsc2þ/2 mice after arterial
injury. Twenty-one days after carotid artery injury, Tsc2þ/2
mice with rapamycin treatment showed a 4-fold reduction in
I/M ratio compared with those treated with vehicle treatment
(Fig. 4C and D).
a-Elastin peptides activate Rho signaling and decrease
Tsc21/2 SMC proliferation
Despite the increased proliferation of descending aortic
Tsc2þ/2 SMCs, the aortic pathology of Tsc2þ/2 mice failed
to demonstrate any evidence of increased proliferation in
vivo. Since the proliferation of elastin-deficient SMCs
(Eln2/2SMCs) is decreased with the exposure to tropoelastin
or acid hydrolyzed elastin fibers (a-elastin) (29), we sought to
determine whether a-elastin would have a similar effect on
suppressing Tsc2þ/2 SMC proliferation. When SMCs were
treated for 72 h with varying doses of soluble a-elastin, pro-
liferation of the WT SMCs was unaffected, whereas the cell
proliferation of Tsc2þ/2 SMCs was markedly reduced in a
dose-dependent manner (Fig. 5A). To determine whether the
decreased proliferation in mutant SMCs with a-elastin
exposure was due to apoptosis, flow cytometric analysis
using dual staining with propidium iodide (PI) and FITC-
conjugated annexin V was performed after SMCs were
treated with different doses of a-elastin. No significant
increase in apoptosis was found in either the WT or
Tsc2þ/2 SMCs (data not shown).
Previous studies have indicated that elastin regulates SMC
proliferation via a G-protein-coupled signaling pathway (29).
Incubation of the Tsc2þ/2 SMCs with a specific Rho kinase
inhibitor (Y27632) blocked the a-elastin-induced decrease in
cell proliferation (Fig. 5A). Levels of p27kip1 have been pre-
viously implicated controlling proliferation in Tsc mutant
mouse embryonic fibroblasts and astrocytes (30). We found
that the mutant SMCs had diminished levels of p27kip1 com-
pared with WT SMCs at baseline, and p27kip1 levels increased
in mutant SMCs with increasing amounts of a-elastin peptide
(Fig. 5B). a-Elastin treatment of Tsc2þ/2 SMCs was also
found to inhibit mTORC1-p70S6 pathway signaling as
evident by decreased phosphorylation of mTOR and p70S6K,
a previously undescribed effect of a-elastin binding. Despite
the decrease in proliferation, exposure to a-elastin did not
alter the levels of Acta2 or Cnn1 in the Tsc2þ/2 SMCs. There-
fore, a-elastin binding to Tsc2þ/2 SMCs increases p27kip1
levels, inhibits mTOR signaling and decreases proliferation
but fails to induce expression of contractile proteins.
DISCUSSION
This study is the first to examine the etiology of vascular path-
ology associated with TSC2 mutations. The aneurysm-
associated pathology in TSC patients demonstrated subintimal
proliferation of SMCs, suggesting increased SMC prolifer-
ation contributed to the formation of these aneurysms. We
confirmed a thoracoabdominal aortic aneurysm associated
with subintimal SMC proliferation in a child with a TSC2
mutation. We demonstrated that the activation of mTORC1
signaling occurs in aortic SMCs with loss of only one allele
of Tsc2 and leads to de-differentiation of SMCs characterized
by increased proliferation and decreased expression of con-
tractile proteins. Rapamycin treatment effectively reverses
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Figure 4. Histological and morphometric analysis of injured carotid arteries from WT and Tsc2þ/2 mice. (A) Representative photomicrographs of carotid
arteries from WT (top panels) and Tsc2þ/2 (bottom panels) mice stained with H&E for 21 days following no injury (left panels) or injury (right panels).
Scale bars represent 50 mm. Results are representative of seven independent experiments. (B) Neointima area of uninjured and injured carotid artery cross-
sections from WT and Tsc2þ/2 mice. Data represent mean neointima area of seven cross-sections+SD, n ¼ 7. For Tsc2þ/2 uninjured versus injured, P ,
0.01, and for WT injured versus Tsc2þ/2 injured, P , 0.01. I/M ratio of uninjured and injured carotid artery cross-sections from WT and Tsc2þ/2 mice.
Data represent mean I/M ratio of seven cross-sections+SD, n ¼ 7. For Tsc2þ/2 uninjured versus injured, P , 0.01, and for WT injured versus Tsc2þ/2
injured, P, 0.01. Percentage of carotid artery stenosis 21 days following injury in WT and Tsc2þ/2 mice. Data represent mean percent stenosis of seven
cross-sections+SD, n ¼ 7, P,0.05. (C) Representative photomicrographs of H&E-stained carotid arteries from WT (top panels) and Tsc2þ/2 (bottom
panels) mice 21 days following no injury and vehicle treatment (left panels), injury and vehicle treatment (middle panels) or injury and rapamycin treatment
(right panels). Scale bars represent 50 mm. Results are representative of seven independent experiments. (D) I/M ratio of injured carotid artery cross-sections
from vehicle and rapamycin-treated WT and Tsc2þ/2 mice. Data represent mean I/M ratio of seven cross-sections+SD, n ¼ 7 mice. For Tsc2þ/2 uninjured
versus injured with vehicle treatment, P, 0.01; for Tsc2þ/2 injured with vehicle versus injured with rapamycin treatment, P , 0.01; for WT injured with
vehicle treatment versus Tsc2þ/2 injured with vehicle treatment, P , 0.05.
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the proliferation and de-differentiation of Tsc2þ/2 SMCs in
vitro and in vivo, providing evidence that the effect of Tsc2
deficiency on vascular SMCs is primarily driven by increased
mTORC1 signaling. It has previously been shown that in
control SMCs, inhibition of mTORC1 using rapamycin pro-
motes differentiation through the activation of the Akt
pathway and the induction of SMC contractile protein
expression (19). The effectiveness of rapamycin in vivo is
illustrated by the success of rapamycin-eluting stents in pre-
venting stent occlusion due to SMC proliferation (31). These
clinical studies and the data presented here suggest a potential
therapeutic use of rapamycin or rapamycin-eluting stents for
the treatment of aortic aneurysms and potentially other vascu-
lar disease in TSC patients.
Elastin, the predominant extracellular protein in major arteries,
is synthesized and secreted as a monomer, tropoelastin, which is
crosslinked and organized into elastin polymers that form the con-
centric lamellae in the medial layer of arteries (32,33). The layers
Figure 5. Effect of a-elastin exposure on cell proliferation and protein levels in Tsc2þ/2 SMCs. (A) SMCs explanted from WT and Tsc2þ/2 mice were cultured
at a-elastin concentration of 0, 0.5, 1 and 5 mg/ml, respectively, for 72 h. BrdU assay demonstrated that proliferation of Tsc2þ/2 SMCs was inhibited in a dose-
dependent manner. A specific Rho inhibitor (Y27632) could prevent the reduction of Tsc2þ/2 SMC proliferation by a-elastin. (B) Western blot assay demon-
strated that a-elastin-treated Tsc2þ/2 SMCs increased expression level of p27kip1, inhibited mTOR signaling and decreased SMC proliferation. In addition,
a-elastin did not alter expression level of contractile proteins in Tsc2þ/2 SMCs.
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of elastin lamellae alternate with layers of SMCs in elastic arteries
to form a unique structure designed to absorb hemodynamic
forces. A role of elastin in controlling SMC proliferation was
first suggested by the observation that loss-of-function mutations
in one elastin allele lead to supravalvular aortic stenosis, a vascu-
lar disease characterized by fibrocellular SMC proliferation in the
aorta and other arteries (34). Further in vitro studies confirmed
that elastin deficiency increases SMC proliferation rates by
demonstrating increased proliferation of SMCs explanted from
the Eln2/2 mouse (29). Addition of tropoelastin or a-elastin to
these cells decreases SMC proliferation via a G-protein-coupled
signaling pathway. The decreased proliferation occurs without
the induction of the expression of a-actin, a major component
of the SMC contractile unit. Our data indicate that exposure to
a-elastin peptides also decreases proliferation rates of Tsc2þ/2
cells, a change associated with increased p27kip1 protein levels,
suggesting that the anti-proliferative effects of a-elastin binding
are mediated, in part, through p27kip1. Elastin fragments also
decrease mTOR signaling in theTsc2þ/2 SMCs through an unde-
termined mechanism. The observation that a-elastin binding
decreases SMC proliferation through Rho kinase signaling is
counter to the literature on Rho kinase signaling and SMC pro-
liferation. For many years, it has been recognized that the specific
Rho kinase inhibitor, Y27632, suppresses both mitogen-induced
DNA synthesis in SMCs and neointimal proliferation after
balloon-injured carotid arteries in a rat model (35). The suppres-
sion of SMC proliferation with Y27632 is associated with
increased levels of p27kip1. As mentioned earlier, previous
studies have shown that elastin binding decreases the prolifer-
ation rates in Eln2/2 SMCs through Rho kinase signaling.
Although elastin had no effect on WT SMC proliferation rates,
elastin suppressed proliferation in the Tsc2þ/2 aortic SMCs,
associated with increased p27kip1 levels and decreased mTOR
signaling, and a Rho kinase inhibitor blocked these effects.
These results suggest the possibility that elastin binding sup-
presses SMC proliferation resulting from an underlying genetic
mutation (e.g.Eln or Tsc2 deficiency) through Rho kinase signal-
ing pathway, leading to increased p27kip1 levels.
SMCs in the ascending aorta are derived from the neural
crest cells, whereas SMCs in the descending and abdominal
aortas originate from mesodermal cells (22,36,37). Aortic
aneurysms in TSC children involve almost exclusively the
descending and abdominal aorta. Pathological findings of the
TSC-associated aortic aneurysms are similar to the pathology
in the patient reported here, including the loss of elastic fibers,
disruption of the organized structure of the aortic media and
nodular proliferation of SMCs (38–40). Our data indicate
that loss of Tsc2 has a more pronounced effect on
mesodermal-derived SMCs than neural crest-derived SMCs,
and this increased proliferative potential and decreased
expression of contractile proteins of the descending aortic
SMCs may contribute to preferential involvement of the des-
cending aorta in this disorder. The low penetrance of this
aortic complication in TSC patients raises the possibility that
loss of heterozygosity (LOH) for the TSC allele is required
for the increased proliferation of the SMCs associated with
the aortic aneurysm formation. It is important to note that
the Tsc2þ/2 SMCs demonstrated increased proliferation
in vitro without evidence of LOH. In addition, the consistent
increase in SMC proliferation in response to carotid injury
in the Tsc2þ/2 mouse implies that LOH is not required for
the in vivo increase in SMC proliferative response when com-
pared with control mice. Further studies will determine
whether LOH is involved in the aortic aneurysm formation
in TSC patients. At the same time, aortic imaging of a
cohort of TSC children will determine whether aortic dilata-
tion is present frequently in TSC children but resolves and
does not progress to aneurysm formation.
The vascular disease and increased SMC proliferation
associated with TSC2 mutations have similarities to vascular
disease in patients with neurofibromatosis type I (NF1)
(41,42). Similar to TSC, one of the less studied and most
poorly recognized complications of NF1 is the vasculopathy
that affects arteries ranging in size from the proximal aorta
to small arteries and may produce vascular diseases, including
aneurysms. Similar to the pathological lesions observed in
TSC patients, the lesions in the small vessels of NF1 patients
are characterized by medial and intimal SMC hyperplasia
(43,44). NF1 is due to heterozygous mutations in the NF1
gene, which encodes neurofibromin, a tumor-suppressor that
functions in part as a negative regulator of RAS signaling
(45). In the mouse, partial or complete loss of neurofibromin
expression in SMCs leads to marked SMC intimal hyperproli-
feration in response to vascular injury (46,47). Similar to the
Tsc2þ/2 mutant SMCs, SMCs explanted from the mice
lacking or deficient in NF1 expression displayed increased
proliferation in vitro compared with WT SMCs (46,48).
In summary, SMCs harboring loss of one allele of Tsc2 have a
significantly altered phenotype of increased proliferation and
decreased contractile protein expression when compared with
WT SMCs. Rapamycin effectively reversed the abnormal SMC
phenotype, whereas binding to elastin peptides reversed the pro-
liferation but failed to induce expression of contractile proteins.
On the basis of these data, we propose that Tsc2þ/2 mutant
SMCs proliferate normally when associated with elastin fibers
but may fail to fully express the repertoire of proteins required
for normal contractile function. This defect in SMCs is more pro-
nounced in the descending aorta than the ascending most likely
due to different cell lineage origins of the SMCs in these two vas-
cular beds. It is also important to note that the relative ratios of
elastin to collagen progressively decrease from the ascending
aorta to the abdominal aorta (32), and this may contribute to
the unique presentation of the disease primarily in the abdominal
aorta in TSC patients. This decrease in contractile proteins in the
SMCs may lead to decreased ability to contract with each pulse
wave and contribute to aneurysm formation, consistent with a
pathway previously suggested for ascending aneurysms for-
mation (49). Future studies will further delineate the molecular
pathogenesis of these aneurysms in TSC patients, information
that has the potential to contribute to our understanding of the
pathogenesis of the most common type of aortic aneurysm,
abdominal aortic aneurysms.
MATERIALS AND METHODS
Patient material and mutation analysis
The Institutional Review Board at the University of Texas
Health Science Center at Houston (UTHSCH) approved this
study. All patient material and records were collected after
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approved consent was signed. Analysis of the TSC1 and TSC2
genes was performed by Athena Diagnostics, Inc.
Animals
We used 6- to 8-week-old WT and age-matched Tsc2þ/2
mice, which contain a deletion of Tsc2 involving exons 2
through 4 (20,21). The WT and heterozygous mice are of
mixed 1291/SvJ and C57BL/6 background. The animals
were cared for according to the NIH Guide for the Care and
Use of Laboratory Animals. Ketamine–xylazine was used to
anesthetize mice prior to euthanasia. The thorax was opened
beneath the xiphoid process. An incision was made in the
right atrium to provide an outlet for blood and perfusate.
The left ventricle was then punctured with a 22-gauge
needle aimed at the direction of the left ventricular outflow
tract. The needle was attached to a perfusion system that pro-
vided initial perfusion with normal saline at 100 mmHg. This
continued until outflow from the right atrial incision was clear
and the liver appeared blanched (50). At this time point, both
WT and Tsc2þ/2 mice were divided into two groups. Half of
the mice were perfused with 10% formalin in phosphate buffer
saline (PBS) at 100 mmHg for 3 min. The aorta was carefully
harvested from its root to the renal arteries. The excised aorta
was fixed in 10% neutral-buffered formalin and processed for
routine paraffin embedding. For another half of mice, whole
aortas were collected under sterile conditions and put into
biopsy medium [Waymouth’s medium (Invitrogen) sup-
plemented with 100 U/ml of penicillin, 100 mg/ml of strepto-
mycin, 250 ng/ml of amphotericin, 2.5 mM L-glutamine,
1 mM MEM non-essential amino acids, 100 mM HEPES
buffer and sodium bicarbonate].
Carotid artery injury and rapamycin treatment
Fourteen 8-week-old WT and 14 age-matched Tsc2þ/2 mice
were anesthetized by intraperitoneal injection of 2.5%
avertin. The left common carotid artery was ligated near its
bifurcation with the use of 5-0 silk. The wound was sutured.
Animal survival was .95%. For morphological analysis,
animals were perfused with normal saline and fixed with
10% phosphate-buffered formalin at physiological pressure
for 3 min. Left and right carotid arteries were removed in
block, further fixed for 16 h and paraffin-embedded without
further dissection. Because lesion thickness varies longitudin-
ally, the entire length of the left and right carotid arteries was
sectioned and examined for identification of the apex of the
leision, which displays the smallest lumen. For morphometric
analyses, images of hematoxylin and eosin (H&E)-stained
cross-sections of injured and control arteries were analyzed
using Image J. Perimeters of the lumen, IEL and external
elastic lamina (EEL) were obtained by tracing the contours
on digitized images. Intimal thickness (distance between
lumen and IEL) and medial thickness (distance between IEL
and EEL) were automatically calculated. Percent lumen steno-
sis was calculated as: (intima area/IEL area)  100. For the
rapamycin treatment, 2 mg/kg rapamycin (A.G. Scientific,
Inc.) in dimethyl sulfoxide (DMSO) or DMSO alone
(vehicle) was administrated once intraperitoneally at 4 h fol-
lowing injury and continued for 2 weeks by 2 mg/kg daily.
Cell culture
Ascending aorta/arch and descending aortas were separated
after the origin of the left subclavian artery. Each part of the
aorta was successively washed with 70% ethanol, PBS and
aortic biopsy medium. A scalpel was used to remove the endo-
thelial cell layers and the adventitia, and the remaining medial
layer of aorta from mutant and WT mice was chopped into
small pieces and put to digestion overnight for 16 h in 5 ml
of aortic biopsy medium supplemented with 0.1 mg/ml of col-
lagenase type I, 0.01875 mg/ml of elastase type I and
0.0250 mg/ml of soybean trypsin inhibitor. At the end of incu-
bation, the digestion was stopped with 2.5 ml of fetal bovine
serum (FBS) and 2.5 ml of complete SMC medium [SmBM
from Lonza supplemented with 20% FBS, 100 U/ml of peni-
cillin, 100 ug/ml of streptomycin, 250 ng/ml of amphotericin,
0.5 ml of insulin, 1.0 ml of rhEGF, 0.5 ml of rhFGF, 2 mmol/l
of L-glutamine, 20 mmol/l of HEPES, 1 mmol/l of sodium pyr-
uvate (Clonetics)] (46). Cells and tissue were spun down,
washed once with complete SMC medium, spun down
again, resuspended in complete SMC medium and seeded
into flasks for further experiments. The identity of these
cells as SMCs was verified by staining for smooth muscle
a-actin (mouse monoclonal antibody; Sigma) at each
passage (.95% of cells stained positive for smooth muscle
a-actin). SMCs were cultured in complete SMC medium in
a 378C, 5% CO2-humidified incubator. Four independent cell
lines were explanted from WT mice and mutant mice, using
three mice in each group. The results presented are represen-
tative of duplicate experiments done on these SMCs using
matched passage levels between WT and mutant SMCs,
with all studies done on SMCs at less than passage 5.
For rapamycin treatment, SMCs were plated at a density of
100 cells/mm2. After 8 h incubation in serum-containing
media as noted earlier, the cells were serum-starved for 24 h
for cell cycle synchronization. The cells were treated with
20 nmol/l of rapamycin (MP Biomedicals) or with DMSO
(vehicle control) in SmBM plus 5% FBS for 24, 48, 72 h.
The medium was refreshed every 24 h. For a-elastin and
Rho kinase inhibitor treatment, SMCs were seeded in a
96-well tissue culture plate at a density of 20 000 cells/well
for 8 h in serum-containing media as noted earlier. The cells
were serum-starved for 24 h for cell cycle synchronization.
Cells were then cultured with SmBM containing 5% FBS
plus a-elastin (at concentration of 0, 0.5, 1 and 5 mg/ml,
respectively) in the presence or absence of Rho kinase inhibi-
tor (10 mM, InSolutionTM Rho Kinase Inhibitor, Calbiochem)
for the next 72 h.
Histological and immunohistochemical studies
The excised aorta was fixed in 10% neutral-buffered formalin
and processed for routine paraffin embedding. Aorta tissue
cross-sections (6 mm) were stained with H&E in a standard
manner. Immunohistochemical staining was performed
using an avidin–biotin complex system. Sections were
de-paraffinized and rehydrated by immersing in xylenes and
graded alcohol series, followed by heat-induced epitope retrie-
val using 10 mM citrate buffer, pH 6.0. Following antigen
recovery, aortic tissue slides were incubated for 1 h with
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blocking reagent. The sections were incubated overnight at
48C with mouse-monoclonal a-smooth muscle actin
(a-SMA) antibody (Sigma, St Louis, MO, USA). After
washing in PBS and incubation with a biotinylated secondary
antibody, the slides were treated with peroxidase-conjugated
biotin–avidin complex (Vectastain ABC-AP Kit, Vector Lab-
oratories, Burlingame, CA, USA). Finally, peroxidase was
revealed by immersion in alkaline phospatase substrate sol-
ution (Vector Red Alkaline Phosphatase Substrate Kit,
Vector Laboratories). Slides were counterstained with hema-
toxylin.
Immunofluorescence of SMCs
To analyze the contractile protein expression and stress fiber
formation in SMCs, cells were immunofluorescently stained
for a-SMA and phalloidin. After cells reached confluence,
they were seeded onto coverslips in six-well plates with the
density of 13 cells/mm2 for 24 h prior to serum-starvation.
After 24 h serum-starvation, cells for baseline were fixed,
and remains were stimulated with 20 nmol/l of rapamycin in
SmBM plus 5% FBS for 72 h. The media was refreshed
every 24 h. Cells were fixed with 4% paraformaldehyde in
0.1 M phosphate buffer for 10 min and washed three times
with cold PBS prior to permeabilization. Permeabilization
and blocking of nonspecific binding sites were performed in
PBS containing 1% bovine serum albumin (BSA) and 0.5%
Tween20. For phalloidin staining, coverslips were incubated
with Texas Red-labeled phalloidin (1:40 in blocking solution)
(Molecular Probes, Eugene, OR, USA) for 30 min at room
temperature and washed three times with PBS. Coverslips
were then treated with antibody to a-SMA (1:100) for 1 h fol-
lowed by fluorescenin isothiocyanate-conjugated secondary
antibody (1:200) for 1 h at room temperature. Nuclei were
counterstained with DAPI (Vector Laboratories), and then ran-
domly chosen fields on each coverslip were imaged by laser
scanning fluorescence microscopy (OLYMPUS IX70) and
analyzed with a deconvolution system (DeltaVision Deconvo-
lution System, Applied Precision, Issaquah, WA, USA).
Cell proliferation assay
DNA incorporation into proliferating cells was quantified
using a BrdU Cell Proliferation Kit (Chemicon, Cat.2752).
Briefly, SMCs were seeded in 96-well plates (20 000 cells/
well) and grown for 8 h in SmBm containing 20% FBS. The
cells were serum-starved for 24 h for cell cycle synchroniza-
tion. Subsequently, the cells were treated with DMSO or rapa-
mycin for an additional 72 h. The media were refreshed every
24 h. Then, BrdU was added to the culture medium. BrdU
incorporation was quantified by ELISA according to the man-
ufacturer’s instructions.
FACS analysis
Cell cycle was determined by flow cytometry in PI-stained
cells. At each time point, the cells were serum-starved for
24 h for cell cycle synchronization. Then, cells were digested
with trypsin–EDTA from culture plates. Cells (2  106) were
collected by low-speed centrifugation, washed with cold PBS,
recollected by centrifugation, fixed with 70% ethanol at room
temperature for at least 30 min, then stored at 2208C over-
night. After washing twice, cells were stained with 50 mg/ml
of PI, and 10 mg/ml of RNase A (Bachem California, Tor-
rance, CA, USA) was added 30 min before flow cytometry
analysis. Red fluorescence was measured with a FACScan
(Becton Dickinson, San Jose, CA, USA). DNA content and
cell cycle profiles were analyzed to determine fractions of
the population in each phase of the cell cycle (G0/G1, S,
G2/M).
SDS–PAGE and western blotting analysis
Cells were washed twice with ice-cold PBS and lysed in RIPA
buffer (50 mM of Tris, pH 7.5, 150 mM of NaCl, 1% NP-40,
0.5% sodium deoxycholate and 0.1% SDS) supplemented
with protease inhibitor cocktail (Sigma) and phosphatase
inhibitor cocktail (Sigma). Protein concentration was deter-
mined by the Bio-Rad protein assay. Total cell lysates
(10 mg) were separated by SDS–PAGE with Tris–HCl gel
(Ready Gel, Bio-Rad, Hercules, CA, USA), followed by trans-
fer to polyvinylidene difluoride membranes (Immobilon-P,
Millipore, Bedford, MA, USA). Membranes were incubated
in blocking buffer (5% nonfat milk in T-PBS) for 1 h and
immunoblotted with primary antibody diluted in 5% BSA
(Sigma). Membranes were probed with horseradish
peroxidase-conjugated secondary antibody (Jackson Immu-
noResearch Laboratories, West Grove, PA, USA). Western
blots were visualized by the enhanced chemiluminescence
technique (Amersham ECL Western Blotting Detection
Reagents, GE Healthcare, Piscataway, NJ, USA). Primary
antibodies include anti-TSC2, anti-TSC1, anti-a-tubulin
(11H10), anti-mTOR (7C10), anti-Phospho-mTOR
(Ser2448), anti-p70 S6 Kinase, anti-Phospho-p70 S6 Kinase
(Thr389), anti-S6 (5G10), anti-Phospho S6 (Ser240/244) (all
from Cell Signaling Technology), anti-Phospho-4E-BP1
(Thr45)(from Signalway Antibody), anti-SM myosin, anti-
a-SMA, anti-calponin, anti-GAPDH (all from Sigma).
qPCR analysis
Total cellular RNA was extracted using TRI reagent (Sigma)
according to the manufacturer’s protocol. qPCR analysis was
carried out using pre-designed TaqMan assays from Applied
Biosystems using manufacturer’s protocols and reagents and
run on an ABI Prism 7700 Sequence Detection System
(Applied Biosystems).
Statistical analysis
All values are expressed as means+SD. Statistical differ-
ences between Tsc2þ/2 cells and controls were analyzed by
a Student’s t-test. Morphometric analysis of carotid artery
was done by one-way ANOVA. Differences were considered
statistically significant at values of P , 0.05. Data for cell
culture experiments represent three experiments in triplicates
using separate cultures.
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